THOMAS PAUL 4

What Happened

• Thomas Paul, a member of Axogen’s Board of Directors, received a grant of 5,579 restricted stock units (RSUs) on June 24, 2026. The filing reports a $0.00 per-share acquisition price because this was an equity award rather than an open-market purchase. The grant is reported with an approximate total value of $235,000 based on the company’s valuation for director compensation.

Key Details

• Transaction date: June 24, 2026; Form 4 filed June 26, 2026.
• Award: 5,579 RSUs at $0.00 per share (derivative award).
• Estimated grant value: $235,000 (per footnote describing the valuation used to set the award).
• Vesting: RSUs vest on June 24, 2027 (one-year cliff), per footnote.
• What RSUs mean: Each RSU represents a contingent right to receive one share of Axogen common stock upon vesting (footnote F1).
• Shares owned after transaction: Not disclosed in the filing.

Context

• This is an annual director equity grant for service on the Board (routine compensation, not a market purchase or sale). RSUs are not immediate stock — they convert to shares only if and when they vest, and therefore do not represent currently tradeable shares.